Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy
· Delayed Price · Currency is EUR 53.75
-0.30 (-0.56%)
Jul 7, 2025, 5:38 PM CET
BIT:REC Revenue
Recordati Industria Chimica e Farmaceutica had revenue of 679.96M EUR in the quarter ending March 31, 2025, with 11.87% growth. This brings the company's revenue in the last twelve months to 2.41B, up 12.85% year-over-year. In the year 2024, Recordati Industria Chimica e Farmaceutica had annual revenue of 2.34B with 12.45% growth.
Revenue (ttm)
2.41B
Revenue Growth
+12.85%
P/S Ratio
4.62
Revenue / Employee
531.77K
Employees
4,583
Market Cap
11.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.34B | 259.23M | 12.45% |
| Dec 31, 2023 | 2.08B | 229.02M | 12.36% |
| Dec 31, 2022 | 1.85B | 273.23M | 17.29% |
| Dec 31, 2021 | 1.58B | 131.21M | 9.06% |
| Dec 31, 2020 | 1.45B | -32.98M | -2.23% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DiaSorin | 1.21B |
| Amplifon | 2.42B |
| EL.En. | 577.19M |
| Philogen | 77.65M |
| Pharmanutra | 116.15M |
| Garofalo Health Care | 470.20M |
| Safilo Group | 993.22M |
| GPI S.p.A. | 509.93M |
Recordati Industria Chimica e Farmaceutica News
- 13 days ago - Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA - Benzinga
- 13 days ago - Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges - Benzinga
- 13 days ago - Amarin inks licensing deal with Recordati for lead drug Vazkepa - Seeking Alpha
- 2 months ago - Recordati reports Q1 results - Seeking Alpha
- 2 months ago - RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2% - GlobeNewsWire
- 5 months ago - There is still such a huge need to do better with rare diseases: Recordati CEO - CNBC
- 7 months ago - Angelini Pharma Said to Discuss Combination With CVC’s Recordati - BNN Bloomberg
- 8 months ago - Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase - CNBC